000538 云南白药
2026/06 - 中期
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入21,884,0762.95%41,186,99940,033,30139,111,29236,488,373
减:营业总成本18,422,7093.29%36,210,22435,206,79735,082,75032,087,168
    其中:营业成本15,305,9154.14%29,032,92328,864,76628,744,51826,883,485
               财务费用18,175-178.66%(46,890)(155,555)(259,244)(342,878)
               资产减值损失(24,068)-42.34%(258,372)(91,231)(58,128)(664,339)
公允价值变动收益129,32584.65%110,489136,837123,566(619,903)
投资收益601,930-28.31%1,042,986776,937779,011868,198
    其中:对联营企业和合营企业的投资收益615,751-21.41%989,142774,280628,532732,233
营业利润4,274,0841.27%6,038,8955,711,6224,830,5063,371,279
利润总额4,282,5571.20%6,043,2715,684,7204,818,0123,377,002
减:所得税费用585,309-0.33%853,330917,647695,451536,593
净利润3,697,2481.44%5,189,9414,767,0724,122,5612,840,410
减:非控股权益(3,923)-133.56%36,45417,65728,779(160,716)
股东净利润3,701,1711.88%5,153,4874,749,4154,093,7823,001,126

市场价值指针
每股收益 (元) *2.0701.47%2.8902.6602.2901.900
每股派息 (元) *1.0381.86%2.6022.3982.0771.520
每股净资产 (元) *22.9641.40%22.44321.76422.19421.428
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容